2.要約中間連結財務諸表及び主な注記
(1)要約中間連結財政状態計算書
(単位:百万円)
| 前連結会計年度 (2024年3月31日) | | 当中間連結会計期間 (2024年9月30日) |
資産 | | | |
流動資産 | | | |
現金及び現金同等物 | 14,473 | | 27,456 |
営業債権及びその他の債権 | 22,152 | | 15,261 |
契約資産 | 21 | | 2,528 |
その他の金融資産 | 3,619 | | 3,897 |
棚卸資産 | 249 | | 349 |
その他の流動資産 | 879 | | 1,416 |
流動資産合計 | 41,395 | | 50,908 |
非流動資産 | | | |
有形固定資産 | 12,724 | | 13,477 |
のれん | 55,974 | | 58,040 |
無形資産 | 5,768 | | 5,915 |
その他の金融資産 | 4,541 | | 5,596 |
繰延税金資産 | 1,771 | | 1,898 |
その他の非流動資産 | 277 | | 311 |
非流動資産合計 | 81,057 | | 85,239 |
資産合計 | 122,452 | | 136,148 |
負債及び資本 | | | |
負債 | | | |
流動負債 | | | |
借入金 | 22,352 | | 20,111 |
営業債務及びその他の債務 | 5,975 | | 7,197 |
リース負債 | 1,086 | | 1,133 |
未払法人所得税 | 1,316 | | 1,179 |
契約負債 | 1,462 | | 2,548 |
その他の流動負債 | 2,041 | | 2,092 |
流動負債合計 | 34,235 | | 34,263 |
非流動負債 | | | |
借入金 | 6,574 | | 17,867 |
リース負債 | 7,819 | | 7,695 |
退職給付に係る負債 | 205 | | 297 |
引当金 | 472 | | 478 |
繰延税金負債 | 699 | | 696 |
契約負債 | 1,535 | | 2,179 |
その他の非流動負債 | 223 | | 226 |
非流動負債合計 | 17,530 | | 29,441 |
負債合計 | 51,765 | | 63,704 |
資本 | | | |
資本金 | 25,099 | | 25,110 |
資本剰余金 | 28,304 | | 28,204 |
自己株式 | △3 | | △3 |
その他の資本の構成要素 | 23 | | 28 |
利益剰余金 | 17,166 | | 18,735 |
親会社の所有者に帰属する持分合計 | 70,590 | | 72,075 |
非支配持分 | 96 | | 368 |
資本合計 | 70,686 | | 72,444 |
負債及び資本合計 | 122,452 | | 136,148 |
E3530844830株式会社JMDCJMDC Inc.四半期第7号参考様式 [IFRS](連結)(一般2Q)IFRStrueCTE2024-04-012024-09-30Q22025-03-312023-04-012023-09-302024-03-311falsefalsefalse448302024-09-30jpigp_cor:TreasurySharesIFRSMember448302024-04-012024-09-30jpigp_cor:TreasurySharesIFRSMember448302024-03-31jpigp_cor:TreasurySharesIFRSMember448302024-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember448302024-09-30jpigp_cor:RetainedEarningsIFRSMember448302024-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember448302024-09-30jpigp_cor:ShareAcquisitionRightsIFRSMember448302024-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember448302024-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember448302024-09-30jpigp_cor:CapitalSurplusIFRSMember448302024-09-30jpigp_cor:ShareCapitalIFRSMember448302024-04-012024-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember448302024-04-012024-09-30jpigp_cor:RetainedEarningsIFRSMember448302024-04-012024-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember448302024-04-012024-09-30jpigp_cor:ShareAcquisitionRightsIFRSMember448302024-04-012024-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember448302024-04-012024-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember448302024-04-012024-09-30jpigp_cor:CapitalSurplusIFRSMember448302024-04-012024-09-30jpigp_cor:ShareCapitalIFRSMember448302024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember448302024-03-31jpigp_cor:RetainedEarningsIFRSMember448302024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember448302024-03-31jpigp_cor:ShareAcquisitionRightsIFRSMember448302024-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember448302024-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember448302024-03-31jpigp_cor:CapitalSurplusIFRSMember448302024-03-31jpigp_cor:ShareCapitalIFRSMember448302023-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember448302023-09-30jpigp_cor:RetainedEarningsIFRSMember448302023-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember448302023-09-30jpigp_cor:ShareAcquisitionRightsIFRSMember448302023-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember448302023-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember448302023-09-30jpigp_cor:CapitalSurplusIFRSMember448302023-09-30jpigp_cor:ShareCapitalIFRSMember448302023-04-012023-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember448302023-04-012023-09-30jpigp_cor:RetainedEarningsIFRSMember448302023-04-012023-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember448302023-04-012023-09-30jpigp_cor:ShareAcquisitionRightsIFRSMember448302023-04-012023-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember448302023-04-012023-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember448302023-04-012023-09-30jpigp_cor:CapitalSurplusIFRSMember448302023-04-012023-09-30jpigp_cor:ShareCapitalIFRSMember448302023-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember448302023-03-31jpigp_cor:RetainedEarningsIFRSMember448302023-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember448302023-03-31jpigp_cor:ShareAcquisitionRightsIFRSMember448302023-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember448302023-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember448302023-03-31jpigp_cor:CapitalSurplusIFRSMember448302023-03-31jpigp_cor:ShareCapitalIFRSMember448302023-09-30jpigp_cor:TreasurySharesIFRSMember448302023-03-31jpigp_cor:TreasurySharesIFRSMember448302023-04-012023-09-30jpigp_cor:TreasurySharesIFRSMember448302024-09-30jpigp_cor:NonControllingInterestsIFRSMember448302024-04-012024-09-30jpigp_cor:NonControllingInterestsIFRSMember448302024-03-31jpigp_cor:NonControllingInterestsIFRSMember448302024-11-05448302024-09-30448302024-04-012024-09-30448302023-09-30448302023-04-012023-09-30448302024-03-31448302023-03-31448302023-09-30jpigp_cor:NonControllingInterestsIFRSMember448302023-04-012023-09-30jpigp_cor:NonControllingInterestsIFRSMember448302023-03-31jpigp_cor:NonControllingInterestsIFRSMember448302024-04-012024-09-30jpcrp_cor:ReportableSegmentsMember448302024-04-012024-09-30tse-scediffr-44830:HealthcareBigDataReportableSegmentMember448302024-04-012024-09-30tse-scediffr-44830:TeleMedicineReportableSegmentMember448302024-04-012024-09-30tse-scediffr-44830:DispensingPharmacySupportReportableSegmentMember448302024-04-012024-09-30jpcrp_cor:ReconcilingItemsMember448302023-04-012023-09-30jpcrp_cor:ReportableSegmentsMember448302023-04-012023-09-30tse-scediffr-44830:HealthcareBigDataReportableSegmentMember448302023-04-012023-09-30tse-scediffr-44830:TeleMedicineReportableSegmentMember448302023-04-012023-09-30tse-scediffr-44830:DispensingPharmacySupportReportableSegmentMember448302023-04-012023-09-30jpcrp_cor:ReconcilingItemsMemberiso4217:JPYxbrli:pureiso4217:JPYxbrli:shares